-transparent.png){kind=logo}
Two new beta-lactam antibiotics, moxalactam and cefotaxime, were administered to two groups of patients with clinical indications for cephalosporin therapy and bacteriologically confirmed infection. The ten patients receiving moxalactam included five patients with impaired renal function; the ten receiving cefotaxime included seven with impaired renal function (serum creatinine greater than 1.3 mg/dl). Antibiotics were administered for seven days in dosages adjusted to the level of renal function. Serum trough levels, measured by microbiological assay, were within the therapeutic range: moxalactam median, 3 micrograms/ml (range, 0.6-20 micrograms/ml) and cefotaxime median, 2.9 micrograms/ml (range, 0.5-16 micrograms/ml).
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
November 1986,
Medicina clinica,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
January 1981,
Arzneimittel-Forschung,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
September 1984,
The Journal of antimicrobial chemotherapy,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
January 1982,
Reviews of infectious diseases,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
November 1990,
European journal of haematology,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
March 1986,
Medicina clinica,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
September 1981,
The Journal of antimicrobial chemotherapy,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
June 1981,
The Journal of antimicrobial chemotherapy,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
January 1980,
Acta clinica Belgica,
K Andrassy, and
J Koderisch, and
S Fritz, and
E Ritz
January 1981,
Arzneimittel-Forschung,
